JOURNAL ONKOLOGIE – STUDIE

Glioma Brain Tumours - E12513 - SensiScreen Glioma

Studien-Informationen Einschlusskriterien Studien-Rationale Studien-Arme Geprüfte Regime

Rekrutierend

NCT-Nummer:
NCT04539431

Studienbeginn:
Januar 2022

Letztes Update:
24.01.2022

Wirkstoff:
-

Indikation (Clinical Trials):
Glioma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
Ente Ospedaliero Cantonale, Bellinzona

Collaborator:
Istituto Cantonale di Patologia, Neurocenter of Southern Switzerland,

Studienleiter

Milo Frattini, PhD
Study Chair
Institute of Pathology

Kontakt

Milo Frattini, PhD
Kontakt:
Phone: + 41 (0)91 816 08 05
E-Mail: milo.frattini@eoc.ch» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

Institute of Pathology Ente Ospedaliero Cantonale
6600 Locarno
SwitzerlandRekrutierend» Google-Maps
Ansprechpartner:
Milo Frattini, PhD
Phone: + 41 (0)91 816 08 05
E-Mail: milo.frattini@eoc.ch» Ansprechpartner anzeigen

Studien-Informationen

Brief Summary:

Validation of a new platform for the molecular characterization of patients affected by

glioma. The new platform includes a series of faster, less expensive real-time PCR

methodologies that, in comparison to standard analyses (DS, MS-PCR), are also characterized

by higher sensitivity and consequently can be able to identify mutations in ctDNA extracted

from liquid biopsies as well. The development of these assays will allow the analysis of

molecular markers alteration even in liquid biopsies, providing a less invasive sampling than

tissue biopsies, a procedure that sometimes is characterized by side effects or that allow

the collection of few tissues for the histological and molecular diagnosis.

This study will not interfere with the patients routine treatment pathway and there will be

no deviation from the standard of care: the molecular characterization of the tissues will be

performed according to the standard diagnostic routine using the currently approved

methodologies. For the retrospective study, it will be used the left-over DNA. For the

cohort, that includes the collection and the subsequent analysis of liquid biopsies

(prospective study), blood and CSF will be sampled during surgery.

The mutations in the molecular markers will be analyzed in tissue as well as in plasma and

CFS samples by the new real-time based assays. Then, the qualitative and quantitative values

obtained on liquid biopsies with the new methodology will be compared to the results of the

standard methodologies already obtained, for diagnostic routine, on surgical tissue samples

of the same patients.

Ein-/Ausschlusskriterien

Retrospective Cohort

Inclusion Criteria:

- Patient with available tissue material or with available molecular data concerning the

tissue biopsy obtained during surgery and analyzed for diagnosis

Exclusion Criteria:

- Insufficient amount of tumor cells in the tissue biopsy for the molecular

characterization

- Inability to consent and follow the procedures of the study (for alive patients)

Prospective Cohort

Inclusion Criteria:

- Age ≥ 18 years old

- Affected by suspected glioma and requiring surgery

- Patient with available tissue material or with available molecular data concerning the

tissue biopsy obtained during surgery and analyzed for diagnosis

- Written informed consent

Exclusion Criteria:

- Insufficient amount of tumor cells in the tissue biopsy for the molecular

characterization

- Inability to consent and follow the procedures of the study

- Women who are pregnant or breast feeding

Studien-Rationale

Primary outcome:

1. Demonstration that the new methodology improves the features (Time Frame - 2 hours):
Demostrate that are found at least the same number of mutations in comparison with respect to standard tests

Studien-Arme

Retrospective
The cases with glioma will be identified in the databases of hospital, the material will be preliminarily evaluated in order to see if there is sufficient tissue left for analysis.
Prospective
A blood sample for molecular analyses will be collected in all the cases, CSF samples will be taken only if recommended by the normal surgical routine.

Geprüfte Regime

validation of new technologies:
Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity

Quelle: ClinicalTrials.gov

Sie können folgenden Inhalt einem Kollegen empfehlen:

"Glioma Brain Tumours - E12513 - SensiScreen Glioma"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!